Fidelity Management & Research Co has recently announced that it has increased stake in Viking Therapeutics Inc (NASDAQ:VKTX) by 0.19%. After grabbing 14.94 million shares, the institutional investor is now in possession of 28523.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 14.94% having worth around $146.57 million. Moreover, SSgA Funds Management, Inc. increased its share by 1.59 million to have a control over 6.41 million shares. And BlackRock Fund Advisors raised its holdings to 0.26 million shares by acquiring 5.92 million shares or 5.92% of the stake.
Viking Therapeutics Inc (VKTX) concluded trading on 12/14/23 at a closing price of $19.22, with 3.82 million shares of worth about $73.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.43% during that period and on Thursday the price saw a loss of about -0.98%. Currently the company’s common shares owned by public are about 100.03M shares, out of which, 89.39M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 77 times over the past 12 months. They bought 1,963,236 shares in 43 of the transactions. In 34 selling transactions, insiders dumped 1,764,159 shares.
SPDR S&P Biotech ETF, Fidelity Growth Company Fund, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Viking Therapeutics Inc SPDR S&P Biotech ETF is currently holding 4.86 million shares of worth totaling $47.63 million. The company recently came buying 29013.0 shares which brought its stake up to 4.85% of the company’s outstanding shares. Fidelity Growth Company Fund bought 32290.0 shares, after which its hold over company’s outstanding shares expand to 3.33%, leaving 3.33 million shares with the mutual fund that have a worth of about $32.62 million. Vanguard Total Stock Market ETF, after buying 2.81 million shares, have now control over 2.81% of the stake in the company. It holds 34100.0 shares of worth $27.59 million.
However, the stock later moved at a day high price of 19.91, or with a loss of -0.98%. Stock saw a price change of 6.54% in past 5 days and over the past one month there was a price change of 72.07%. Year-to-date (YTD), VKTX shares are showing a performance of 104.47% which increased to 428.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.59 but also hit the highest price of $25.72 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 2.43 million. The stock is currently trading 36.33% above its 20-day simple moving average (SMA20), while that difference is up 61.64% for SMA50 and it goes to 24.62% higher than SMA200.
Fidelity Management & Research Co acquired 14.94 million shares of Viking Therapeutics Inc having value of about $146.57 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 28523.0 shares in the company valued at close to $548212.06, or have control over 0.19% stake in the company. Viking Therapeutics Inc (NASDAQ: VKTX) currently have 100.03M outstanding shares and institutions hold larger chunk of about 75.71% of that. Holding of mutual funds in the company is about 41.62% while other institutional holders and individual stake holders have control over 9.81% and 34.12% of the stake respectively.
The stock has a current market capitalization of $1.92B and its 3Y-monthly beta is at 0.50. It has posted earnings per share of -$0.92 in the same period. It has Quick Ratio of 28.44 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 8.66% while standing at 8.28% over the month.
Analysts are in expectations that Viking Therapeutics Inc (VKTX) stock would likely to be making an EPS of -$0.25 in the current quarter, while forecast for next quarter EPS is -$0.27 and it is -$1.1 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.28 which is -$0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.26 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -3.19% while it is estimated to decrease by -17.22% in next year. EPS is likely to grow at an annualized rate of 40.00% for next 5-years, compared to annual growth of -2.56% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH MKM on May 31, 2023 offering a Buy rating for the stock and assigned a target price of $32 to it.
